History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History
BATON ROUGE, La., Aug. 6, 2019 /CNW/ -- GB Sciences Louisiana (OTCQB: GBLX) today announced that its medical cannabis products, developed in partnership with LSU AgCenter's Therapeutic Cannabis Program, are available for sale to qualified patients in the state's nine licensed pharmacies. This is the first time that qualified patients have legal cannabis medicine available under Louisiana law, marking a historic turning point for patients, advocates, and regulators.
"This is a watershed moment for our company and the State of Louisiana, reflecting many years of research and development by GB Sciences into the cannabis plant's biopharmaceutical applications," said John Davis, President of GB Sciences Louisiana. "For the first time, medical cannabis patients in Louisiana have access to safe, tested products with formulations designed to improve their health and wellbeing."
"The combined efforts of LSU AgCenter and GBSL's partners - GB Sciences, Inc., and Wellcana Group, LLC, helped bring this historic day to fruition."
The first products from GB Sciences Louisiana, the contracted producer for the LSU AgCenter, are sublingual tinctures sold in 30mL bottles. This first release has three formulations available for patients: THC-Rich, 300mg THC per 30mL bottle (10mg THC per mL); CBD-Rich, 1200mg CBD and 60mg THC per 30mL bottle (40mg CBD and 2mg THC per mL); and Balanced 1:1, 150mg THC and 150mg CBD per 30mL bottle (5mg THC and 5mg CBD per mL).
Patients with qualifying medical conditions must obtain a recommendation for therapeutic cannabis from a certified physician, and recommendations must be filled at one of the state's nine licensed pharmacies. The current qualifying medical conditions are:
- Cancer
- Positive Status for Human Immunodeficiency Virus (HIV)
- Acquired Immune Deficiency Syndrome (AIDS)
- Cachexia or Wasting Syndrome
- Seizure Disorders
- Epilepsy
- Spasticity
- Crohn's Disease
- Muscular Dystrophy
- Multiple Sclerosis
- Glaucoma
- Parkinson's Disease
- Severe Muscle Spasms
- Intractable Pain
- Post-Traumatic Stress Disorder (PTSD)
- Autism Spectrum Disorder
"The LSU AgCenter is excited about the opportunity therapeutic cannabis will provide patients in Louisiana, and we are looking forward to research initiatives that will help us to understand the full potential of this medicinal plant," said LSU Vice President for Agriculture, Bill Richardson.
The LSU AgCenter, in partnership with GB Sciences Louisiana, is one of two official therapeuticcannabis licensees under the Alison Neustrom Act, passed by the state Legislature in 2015.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
About LSU AgCenter
The Louisiana State University Agricultural Center ("LSU AgCenter" or "AgCenter") is an institution under the supervision and management of the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (the "LSU Board of Supervisors"). The AgCenter's mission is to provide the people of Louisiana with research-based educational information that will improve their lives and economic well-being. The LSU AgCenter includes the Louisiana Agricultural Experiment Station, which conducts Agricultural and Renewable Natural Resource-based research, and the Louisiana Cooperative Extension Service, which extends the knowledge derived from research to the people of the state. The LSU AgCenter plays an integral role in supporting agricultural industries, enhancing the environment, and improving the quality of life through its 4-H youth, family and consumer sciences, and community development programs.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
GB Sciences Louisiana
Liz Bianco, [email protected]
SOURCE GB Sciences, Inc.
Share this article